Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lydia Dreosti

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Breast Cancer Research and Treatment|September 23, 2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancerStephen Johnston, Mark Basik, Roberto Hegg, et al.
Gynecologic Oncology|August 9, 2020
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancerAndres Redondo, Nicoletta Colombo, Mary McCormack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Breast Cancer Research and Treatment|September 23, 2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancerStephen Johnston, Mark Basik, Roberto Hegg, et al.
Gynecologic Oncology|August 9, 2020
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancerAndres Redondo, Nicoletta Colombo, Mary McCormack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2013
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trialHatem A Azim, Dominique Agbor-Tarh, Ian Bradbury, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Pageof 1